The Active Cancer Immunotherapy OBI-822, has been granted by URPL of Poland to proceed to Phase III Clinical Trial

1. Date of occurrence of the event: 2022/01/28 2. New drug name or code: Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3. Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system. Clinical trial info: https://www.clinicaltrials.gov/ct2/show/NCT03562637 https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B2%5D=2681 4. Planned […]

This article is password protected.

To view the content, please enter your password in the field below